Welcome to our dedicated page for PERRIGO Co plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
Khoury Roberto reported acquisition or exercise transactions in this Form 4 filing.
PERRIGO Co plc executive Roberto Khoury, EVP and President of CSCI, reported a grant of 113,101 Restricted Stock Units, each representing a contingent right to receive one ordinary share. These RSUs vest on July 8, 2027. Khoury also reported direct ownership of 14,113 ordinary shares following the reported transactions.
Ball David reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc reported that EVP & Chief Business Development Officer David Ball received a grant of 70,688 Restricted Stock Units (RSUs), each representing a contingent right to one ordinary share. These RSUs vest on July 8, 2027. Following the reported transactions, Ball also holds 6,747 ordinary shares directly.
Atkinson Charles reported acquisition or exercise transactions in this Form 4 filing.
PERRIGO Co plc executive Charles Atkinson, EVP, General Counsel & Secretary, received a grant of 123,704 Restricted Stock Units, each representing a contingent right to one ordinary share. These RSUs vest on July 8, 2027. He also holds 5,855 ordinary shares directly.
Winterman Matthew John reported acquisition or exercise transactions in this Form 4 filing.
PERRIGO Co plc executive Matthew John Winterman, EVP, Supply, Ops, Strategy, received a grant of 70,688 Restricted Stock Units, each representing a contingent right to receive one ordinary share. These RSUs vest on July 8, 2027. Following the transactions, he holds 8,365 ordinary shares directly and 70,688 RSUs.
Willis Robert reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc executive Robert Willis, EVP & CHRO, reported an equity compensation update. He received a grant of 60,085 Restricted Stock Units, each representing a contingent right to receive one ordinary share, which vests on July 8, 2027. Following these transactions, he holds 50,568 ordinary shares directly, and 60,085 RSUs tied to future delivery of ordinary shares.
Lennox Abigail reported acquisition or exercise transactions in this Form 4 filing.
PERRIGO Co plc reported that EVP and CSO Abigail Lennox received a grant of 84,826 Restricted Stock Units, each representing a contingent right to receive one ordinary share. These units vest on July 8, 2027. Following the transactions, Lennox holds 4,607 ordinary shares directly.
Perrigo Company plc EVP Matthew John Winterman reported routine equity compensation activity involving Restricted Stock Units and related tax withholding. On July 8, 2026, he exercised RSUs into 17,503 ordinary shares of Perrigo at a reported value of $10.52 per share.
To cover tax obligations, 9,138 ordinary shares were disposed of as a tax-withholding disposition, not an open-market sale. Following these transactions, Winterman directly holds 7,485 ordinary shares and continues to hold additional unvested RSUs that vest in annual installments beginning July 8, 2026.
Perrigo Company plc executive Roberto Khoury reported routine equity-compensation transactions. On 8 July 2026, he exercised 737 Restricted Stock Units into an equal number of ordinary shares at a stated value of $10.52 per share. To cover tax obligations, 385 ordinary shares were disposed of at $10.52 per share.
Following these transactions, Khoury directly held 14,113 ordinary shares and 1,474 Restricted Stock Units, each representing a contingent right to receive one ordinary share that vests in three equal annual installments beginning 8 July 2026.
Perrigo Company plc has detailed the compensation package for Interim President and Chief Executive Officer Albert A. Manzone in a new employment agreement effective July 3, 2026. The agreement covers a fixed term from June 7, 2026 through December 31, 2026, with a possible month-to-month extension of up to 90 days if a permanent CEO is not yet hired.
Under the agreement, Mr. Manzone will receive an annual base salary of $1,270,000 and a one-time cash bonus of $250,000, subject to performance metrics approved by the board and generally payable at the end of the fixed term or upon termination in connection with a change of control. He will also receive a one-time special restricted stock unit grant with a grant-date fair value of $2,500,000 under Perrigo’s 2026 Long-Term Incentive Plan, which vests upon the earlier of one year, the hiring of a permanent CEO, or a qualifying change-of-control termination.
Perrigo Company plc has reinstated its Executive Committee Severance Policy for most executive officers, excluding the Interim CEO and any successor CEO. The policy applies to qualifying terminations without cause or for good reason from June 7, 2026 until 12 months after a new CEO starts.
During this transition period, eligible executives who experience a qualifying termination will receive 1.5 times the sum of base salary and target bonus, paid over an 18‑month severance period. Perrigo will also pay the employer portion of COBRA premiums during that period, provide a pro rata bonus based on actual performance, and offer career transition assistance.
The policy, which was reinstated on June 29, 2026, will terminate at the end of the transition period. All benefits are conditioned on a release of claims and ongoing confidentiality, invention, non-disparagement, non-compete, and non-solicitation obligations.